5-(三氟甲基)-1,3-噁唑-2-胺 | 714972-00-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 中文名称: 5-(三氟甲基)-1,3-噁唑-2-胺
• 中文别名: 5-(三氟甲基)-1,3-恶唑-2-胺
• 英文名称: 5-(trifluoromethyl)oxazol-2-amine
• 英文别名: 5-(Trifluoromethyl)-1,3-oxazol-2-amine
• CAS: 714972-00-6
• 化学式: C₄H₃F₃N₂O
• mdl: MFCD09800568
• 分子量: 152.076
• InChiKey: OUSMDDBAOJWGMN-UHFFFAOYSA-N

物化性质

• 沸点：
  183.4±50.0 °C(Predicted)
• 密度：
  1.502±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  52
• 氢给体数：
  1
• 氢受体数：
  6

安全信息

• 海关编码：
  2934999090
• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H315,H319,H335
• 储存条件：
  室温

反应信息

• 作为反应物：
  描述：

  5-(三氟甲基)-1,3-噁唑-2-胺 、 9H-氧杂蒽-9-甲酰氯 以75%的产率得到9H-xanthene-9-carboxylic acid (5-trifluoromethyl-oxazol-2-yl)-amide
  参考文献：
  名称：

  Fluorinated 9H-xanthene-9-carboxylic acid oxazol-2-yl-amides as potent, orally available mGlu1 receptor enhancers

  摘要：

  Small molecule mGluR1 enhancers, which are 9H-xanthene-9-carboxylic acid [ 1,2,4] oxadiazol-3-yl- and (2H-tetrazol-5-yl)-amides, have been previously reported. Fluorinated 9H-xanthene-9-carboxylic acid oxazol-2-yl-amides with improved pharmacokinetic properties have been designed and synthesized as useful pharmacological tools for the study of the physiological roles mediated by mGlu1 receptors. The synthesis and the structure-activity relationship of this class of positive allosteric modulators of mGlu1 receptors will be discussed in detail. (C) 2009 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2009.01.108
• 作为产物：
  描述：

  3-溴-1,1,1-三氟丙酮 、 氰胺 在 sodium acetate 作用下， 以 叔丁醇 为溶剂， 反应 2.67h， 以6%的产率得到5-(三氟甲基)-1,3-噁唑-2-胺
  参考文献：
  名称：

  Oxazoles as mGluR 1 enhancers

  摘要：

  本发明涉及如规范和权利要求中所定义的羧酰胺衍生物，涉及它们的制备方法，包括它们的制药组合物以及它们作为mGluR1增强剂在治疗和预防神经系统疾病和疾病，如阿尔茨海默病和痴呆症中的用途。

  公开号：

  US20040132792A1

文献信息

• Oxazoles as mGluR1 enhancers
  申请人：Hoffmann-La Roche Inc.

  公开号：US07119113B2

  公开（公告）日：2006-10-10

  The invention relates to carboxamide derivatives as defined in the specification and claims, to a process for their preparation, to pharmaceutical compositions comprising them and to their use as mGluR1 enhancers in the treatment and prevention of neurological disorders and diseases, such as Alzheimer's disease and dementia.

  本发明涉及如规范和权利要求所定义的羧酰胺衍生物，以及它们的制备方法，包括它们的制药组合物和它们作为mGluR1增强剂在神经系统疾病和疾病的治疗和预防中的使用，如阿尔茨海默病和痴呆症。
• Identification of 5-Substituted 2-Acylaminothiazoles That Activate Tat-Mediated Transcription in HIV-1 Latency Models
  作者：William Nguyen、Jonathan Jacobson、Kate E. Jarman、Helene Jousset Sabroux、Leigh Harty、James McMahon、Sharon R. Lewin、Damian F. Purcell、Brad E. Sleebs

  DOI：10.1021/acs.jmedchem.9b00462

  日期：2019.5.23

  The persistent reservoir of cells latently infected with human immunodeficiency virus (HIV)-integrated proviral DNA necessitates lifelong suppressive antiretroviral therapy (ART). Epigenetic targeted compounds have shown promise as potential latency-reversing agents; however, these drugs have undesirable toxicity and lack specificity for HIV. We utilized a novel HEK293-derived FlpIn dual-reporter cell line, which quantifies specific HIV provirus reactivation (LTR promoter) relative to nonspecific host cell gene expression (CMV promoter), to identify the 5-substituted 2-acylaminothiazole hit class. Here, we describe the optimization of the hit class, defining the functionality necessary for HIV gene activation and for improving in vitro metabolism and solubility. The optimized compounds displayed enhanced HIV gene expression in HEK293 and Jurkat 10.6 latency cellular models and increased unspliced HIV RNA in resting CD4+ T cells isolated from HIV-infected individuals on ART, demonstrating the potential of the 2-acylaminothiazole class as latency-reversing agents.
• [EN] 6-AZA-QUINOLINE DERIVATIVES AND RELATED USES<br/>[FR] DÉRIVÉS DE 6-AZA-QUINOLÉINE ET UTILISATIONS ASSOCIÉES
  申请人：[en]BLACK DIAMOND THERAPEUTICS, INC.

  公开号：WO2023039505A1

  公开（公告）日：2023-03-16

  The present disclosure relates compounds of Formula (0): and pharmaceutically acceptable salts and stereoisomers thereof. The present disclosure also relates to methods of preparing the compounds, compositions comprising the compounds, and methods of using the compounds, e.g., in the treatment of cancer.
• Fluorinated 9H-xanthene-9-carboxylic acid oxazol-2-yl-amides as potent, orally available mGlu1 receptor enhancers
  作者：Eric Vieira、Jörg Huwyler、Synèse Jolidon、Frédéric Knoflach、Vincent Mutel、Jürgen Wichmann

  DOI：10.1016/j.bmcl.2009.01.108

  日期：2009.3

  Small molecule mGluR1 enhancers, which are 9H-xanthene-9-carboxylic acid [ 1,2,4] oxadiazol-3-yl- and (2H-tetrazol-5-yl)-amides, have been previously reported. Fluorinated 9H-xanthene-9-carboxylic acid oxazol-2-yl-amides with improved pharmacokinetic properties have been designed and synthesized as useful pharmacological tools for the study of the physiological roles mediated by mGlu1 receptors. The synthesis and the structure-activity relationship of this class of positive allosteric modulators of mGlu1 receptors will be discussed in detail. (C) 2009 Elsevier Ltd. All rights reserved.
• Oxazoles as mGluR 1 enhancers
  申请人：——

  公开号：US20040132792A1

  公开（公告）日：2004-07-08

  The invention relates to carboxamide derivatives as defined in the specification and claims, to a process for their preparation, to pharmaceutical compositions comprising them and to their use as mGluR1 enhancers in the treatment and prevention of neurological disorders and diseases, such as Alzheimer's disease and dementia.

  本发明涉及如规范和权利要求中所定义的羧酰胺衍生物，涉及它们的制备方法，包括它们的制药组合物以及它们作为mGluR1增强剂在治疗和预防神经系统疾病和疾病，如阿尔茨海默病和痴呆症中的用途。